- Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
-
Lee SA, Kim SW, Chang HH, Jung H, Kim Y, Hwang S, Kim S, Park HK, Lee JM
- KMID: 2420909
- Infect Chemother.
- 2018 Sep;50(3):252-262.
- doi: 10.3947/ic.2018.50.3.252
BACKGROUND: Dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG/DRV/c) is reasonable alternative option for patients with existing resistance and/or intolerance to nucleoside reverse transcriptase inhibitors (NRTIs). MATERIAL AND METHODS: All patients... -
- CITED
-
- Close
- SHARE
-
- Close
- The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens
-
Jin S, Kim MH, Park JH, Jung HJ, Lee HJ, Kim SW, Lee JM, Kim S, Chang HH
- KMID: 2170501
- Infect Chemother.
- 2015 Dec;47(4):239-246.
- doi: 10.3947/ic.2015.47.4.239
BACKGROUND: The combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has been the first choice nucleoside reverse transcriptase inhibitor (NRTI) according to many reliable antiretroviral treatment (ART) guidelines because... -
- CITED
-
- Close
- SHARE
-
- Close
